Overall, these data support the superior therapeutic efficacy of coordinated TA, IFNα, and IL-12 delivery compared to IFNα and IL-12 alone and prove that, at the given dose, this therapeutic intervention is safe and well tolerated in mice and can induce the proliferation and expansion of TA reactive CD8+ T cells against naturally occurring TAAs or neoantigens, resulting in effective anti-tumor immunity against distinct mouse models of LM. Here, CD8A is linked to lymphangioma.